ISRCTN39575233
Completed
Not Applicable
A randomized, placebo-controlled, partially blinded (drug versus placebo) trial of early corticosteroid therapy in Vietnamese children and young adults with suspected dengue infection
niversity of Oxford (UK)0 sites225 target enrollmentOctober 21, 2008
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Dengue fever
- Sponsor
- niversity of Oxford (UK)
- Enrollment
- 225
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Aged between 6 and 20 years, either sex
- •2\. Weight at least 20 kg
- •3\. Clinical suspicion of dengue, with a positive rapid test for dengue non\-structural protein 1
- •4\. Fever for less than or equal to 72 hours
- •5\. Informed consent
Exclusion Criteria
- •1\. Signs or symptoms suggestive of any other acute infectious disease
- •2\. Any evidence of significant complications of dengue, e.g., mucosal bleeding, jaundice, neurological compromise, shock, inability to tolerate oral medication
- •3\. Any prior history of serious physical illness, or any chronic condition requiring regular follow up
- •4\. Any history of psychiatric disorder or behaviour disturbance
- •5\. Current or recent (within 3 months) use of any medication other than drugs for symptomatic relief (analgesics, decongestants, etc.)
- •6\. Any history of an adverse drug reaction to any medication
- •7\. Pregnancy (enrolment within one month of last menstrual period \[LMP] in post\-pubertal females)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase II Study of H4:IC31 and BCG revaccination in Healthy Adolescents (040-404)PACTR201512001069358Aeras990
Active, not recruiting
Phase 1
Study of efficacy and safety of VAY736 in patients with relapsing-remitting multiple sclerosisEUCTR2013-002324-16-PLovartis Pharma Services AG96
Active, not recruiting
Phase 1
Study of efficacy and safety of VAY736 in patients with relapsing-remitting multiple sclerosisrelapsing-remitting multiple sclerosisMedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2013-002324-16-CZovartis Pharma Services AG96
Active, not recruiting
Phase 1
A study to asses the effects of cannabidiol (CBD) on liver fat levels with people who have fatty liver diseaseEUCTR2009-017080-41-GBGW Pharma Ltd.25
Completed
Not Applicable
A Blinded, Placebo-Controlled, Randomized, Single Ascending Dose Study in Healthy Male Subjects to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-37822681psychosis10039628NL-OMON30850Johnson & Johnson Pharmaceutical24